Application of IL-27 in preparation of medicine for promoting healing of diabetic wound
Treatment of bone marrow-derived macrophages through IL-27 promotes the polarization of macrophages M1 and M2 on the wounds of diabetic skin, solving the problem of difficulty in healing diabetic foot ulcers and achieving rapid healing of wounds.
Patent Information
- Application Number
- CN202411434960.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-15
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Diabetic foot ulcers are difficult to heal, mainly due to dysregulated macrophage response, which leads to out-of-control inflammatory response and hindered polarization of macrophage M1 to M2, affecting wound healing.
By treating bone marrow-derived macrophages with IL-27, the M1 polarization of macrophages in the wound of diabetic skin is promoted, and M2 polarization is promoted through the IL-27-IL-27rα-p-STAT3 axis, thereby accelerating diabetic wound healing.
IL-27 significantly accelerates the healing process of diabetic wounds by promoting early macrophage M1 polarization and subsequent M2 polarization, providing a potential therapeutic target for diabetic foot ulcers.
Smart Images

Figure CN118949013A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular, relates to the application of IL-27 in the preparation of a medicine for promoting diabetic wound healing. Background Art
[0002] Diabetes is a major cause of death worldwide, and diabetic foot ulcers (DFUs) are one of the most common complications of diabetes. About 15% of diabetic patients experience complications related to DFUs, of which 25% are at risk of lower limb amputation. The occurrence of DFUs is associated with a variety of factors, including ischemia, reactive oxygen species (ROS), neuropathy, infection, impaired immune function, inflammation, vascular problems, fibrosis, etc., all of which make DFUs difficult to heal. DFUs are characterized by high levels of ROS, uncontrolled inflammatory responses, macrophage dysfunction, insufficient angiogenesis, and impaired tissue remodeling. Acute wound healing undergoes four stages: hemostasis, inflammation, proliferation, and remodeling. The inflammatory response is the "engine" that activates the repair process and is strictly regulated during the repair process. Immune cells are recruited to the site of injury to coordinate multicellular healing responses and prevent infection. Macrophages are a type of immune cell that plays a key role in the wound healing process. In the early wound healing process, recruited monocytes are activated by microbial products and inflammatory mediators and transformed into M1 macrophages. M1 macrophages secrete inflammatory cytokines and chemokines such as IL-1β and TNF-α, which activate and attract more immune cells such as macrophages and helper T cells. M1 macrophages are a pro-inflammatory phenotype that helps prevent infection. As the inflammatory response progresses, pro-inflammatory M1 macrophages polarize into anti-inflammatory and pro-healing M2 macrophages. M2 macrophages promote inflammation resolution, angiogenesis, and tissue remodeling by producing anti-inflammatory mediators (such as IL-10 and IL-1 receptor antagonists), growth factors (such as VEGF and TGF-β1), chemokines (such as CXCL1 and CXCL12), and gelatinases. In addition, the sequential activation of M1 and M2 macrophages is also important because they tend to regulate wound healing sequentially. These processes must be strictly controlled for wounds to heal properly. Impaired wound healing in diabetes is associated with dysregulated macrophage responses. An effective acute inflammatory response is beneficial to the wound healing process. A chronic inflammatory response has an adverse effect on the wound healing process. Compared with the normal acute wound inflammatory response, chronic inflammation in diabetic wounds is at a suboptimal level, and the polarization of macrophages M1 to M2 is blocked, resulting in the inability of the wound to heal normally. With a better understanding of the key roles of macrophages at different stages of the wound healing process, promoting the polarization of macrophages from the pro-inflammatory M1 phenotype to the pro-healing M2 phenotype has become an important intervention strategy to promote diabetic wound healing.
[0003] IL-27 is a member of the IL-12 family and a heterodimeric cytokine composed of Epstein-Barr virus-induced gene 3 (Ebi3) and IL-27p28. The gene encoding IL-27 is located on chromosome 16p11. IL-27 regulates downstream cascades by binding to receptors IL-27ra or gp130. IL-27 has been found to be abnormally expressed in a variety of inflammatory autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, inflammatory bowel disease, systemic sclerosis, diabetes, and ankylosing spondylitis. In vivo and in vitro studies have shown that IL-27 plays an anti-inflammatory or pro-inflammatory role by regulating innate and adaptive immune responses, and is involved in the occurrence and development of related diseases. However, the role of IL-27 in diabetic wound healing and its underlying molecular mechanisms are still unclear. Summary of the invention
[0004] The purpose of the present invention is to overcome the above-mentioned defects and deficiencies in the prior art and provide the use of IL-27 in the preparation of a drug for promoting diabetic wound healing.
[0005] The above-mentioned object of the present invention is achieved through the following technical solutions: The present invention uses intraperitoneal injection of streptozotocin (STZ) to construct a diabetic mouse model, and in the presence of lipopolysaccharide (LPS) and high glucose (HG), bone marrow-derived macrophages (BMDM) are treated with IL-27 to explore the role of IL-27 in diabetic skin wounds. In order to evaluate the effect of IL-27 treatment on the polarization of macrophages in diabetic wounds, the present invention detects the expression of iNOS, IL-1β and Arg-1; macrophage IL-27ra knockout mice are used to understand the potential mechanism of IL-27 in promoting the healing of diabetic skin wounds; and hematoxylin-eosin (HE) staining, Masson staining, Western blotting (WB) and immunohistochemistry (IHC) staining are performed to detect the expression of related proteins. In vivo experiments show that supplementation of IL-27 promotes diabetic wound healing. Specifically, the present invention first discovered that IL-27 accelerates diabetic wound healing by promoting the polarization of early macrophage M1 in the wound. Mechanistically, the present invention found that the expression of IL-27 was reduced in diabetic mice, and the phosphorylation activation of STAT3 was inhibited, resulting in the inability of macrophages to effectively undergo M1 polarization. However, supplementation of IL-27 promoted macrophage M1 polarization and then macrophage M2 polarization through the IL-27-IL-27rα-p-STAT3 axis to promote diabetic wound healing. These findings provide evidence for the role of IL-27 in promoting macrophage polarization in diabetic wound healing, indicating that IL-27 may be a potential therapeutic target for diabetic foot ulcers (DFU).
[0006] Therefore, the present invention first provides the use of IL-27 or an IL-27 expression promoter in the preparation of a drug for promoting diabetic wound healing.
[0007] Furthermore, the diabetic wound is a diabetic ulcer.
[0008] Furthermore, the diabetic ulcer is a diabetic foot ulcer.
[0009] Furthermore, the drug can promote the healing of diabetic wounds by promoting the polarization of early macrophages M1 in the wound. Specifically, IL-27 in the drug promotes the polarization of early macrophages M1 in the wound, then downregulates M1 and promotes the polarization of macrophages M2, that is, promotes the downregulation of inflammation, thereby promoting the healing of diabetic wounds.
[0010] Preferably, the drug promotes macrophage polarization and diabetic wound healing via the IL-27-IL-27rα-p-STAT3 axis.
[0011] Furthermore, the dosage of IL-27 in the drug is 7 to 15 ng / mm 2 .
[0012] Preferably, the dosage of IL-27 in the drug is 15 ng / mm 2 .
[0013] Furthermore, the medicine also contains pharmaceutically acceptable excipients.
[0014] Preferably, the auxiliary material is at least one of a diluent, an excipient, a disintegrant, a filler, a binder, a lubricant, a surfactant, and a stabilizer.
[0015] Preferably, the drug is in the form of an injection.
[0016] Preferably, the drug is administered by intradermal injection.
[0017] Compared with the prior art, the present invention has the following beneficial effects: The present invention provides the use of IL-27 in the preparation of a drug for promoting diabetic wound healing. The present invention has found that supplementing IL-27 promotes diabetic wound healing. Specifically, the present invention has found for the first time that IL-27 accelerates diabetic wound healing by promoting early macrophage M1 polarization in the wound. Mechanistically, the expression of IL-27 is reduced in diabetic mice, and the phosphorylation activation of STAT3 is inhibited, resulting in the inability of macrophages to effectively undergo M1 polarization. Supplementing IL-27 promotes macrophage M1 polarization and then macrophage M2 polarization through the IL-27-IL-27rα-p-STAT3 axis to promote diabetic wound healing. These findings provide evidence for the role of IL-27 in promoting macrophage polarization in diabetic wound healing, indicating that IL-27 is a potential therapeutic target for DFU. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 is the expression level of IL-27 in diabetic skin and its effect on diabetic skin wound healing; wherein, A is the construction of diabetic model mice, B is the venous blood glucose level of mice, C is the peripheral blood IL-27 level of mice, D is the relative expression of IL-27 mRNA in mouse skin, E is the immunohistochemical staining result of IL-27 in mouse skin, F is the relative expression of IL-27 in mouse skin, G is the western blot result of IL-27 expression in mouse skin, H is the relative protein level of IL-27 in mouse skin, I is the wound preparation and IL-27 treatment scheme of mice, J is the wound healing after IL-27 treatment, K is the percentage of D8 / D0 wound area after IL-27 treatment, and L is the HE staining image of mouse skin tissue section.
[0019] Figure 2 The effect of adding IL-27 on macrophage M1 polarization and wound healing in diabetic mice; A is the injection of IL-27 on D1 after wound preparation in diabetic mice, B is the H&E staining and F4 / 80, iNOS, and IL-1β immunohistochemical staining results of D2 skin tissue of mice, C is the relative expression of F4 / 80 in D2 skin tissue of mice, D is the relative expression of iNOS in D2 skin tissue of mice, E is the relative expression of IL-1β in D2 skin tissue of mice, F is the injection of IL-27 on D1-D3 after wound preparation in diabetic mice, G is the wound healing after IL-27 treatment, and H is the percentage of wound area on D8 / D0 after IL-27 treatment.
[0020] Figure 3The effects of IL-27 intervention on M2 macrophage polarization, collagen deposition and angiogenesis in the wound of diabetic mice; A shows the injection of IL-27 on D1-D3 after wound preparation in diabetic mice; B shows the results of H&E staining and IL-1β and Arg-1 immunohistochemical staining of D8 skin tissue of mice; C shows the relative expression of IL-1β in D8 skin tissue of mice; D shows the relative expression of Arg-1 in D8 skin tissue of mice; E shows the results of Masson staining and CD31 immunohistochemical staining of D8 skin tissue of mice; F shows the relative collagen expression in D8 skin tissue of mice; and G shows the relative expression of CD31 in D8 skin tissue of mice.
[0021] Figure 4 The effect of IL-27 on the phosphorylation and activation of STAT3 in macrophages; wherein, A is the result of detecting the phosphorylation level of STAT3 in mouse skin tissue, B is the relative protein level of p-STAT3 / β-actin in mouse skin tissue, C is the injection of IL-27 on D1 after wound preparation in diabetic mice, D is the result of STAT3 phosphorylation in mouse D2 skin tissue, and E is the relative expression of STAT3 phosphorylation in mouse D2 skin tissue.
[0022] Figure 5 Figure 3 Effect of knocking down IL-27Rα in macrophages on STAT3 phosphorylation activation and M1 polarization; A is the construction of IL-27Rα knockdown mouse model, B is the genetic identification of mice, C is WB detection of IL-27Rα expression in BMDM cells, D is the relative quantification of IL-27Rα expression in BMDM cells, E is WB detection of STAT3 phosphorylation activation after 1h stimulation of BMDM cells with LPS, HG and IL-27, F is the relative protein level of p-STAT3 / β-actin, G is the relative mRNA level of iNOS, H is the relative mRNA level of IL-1β, I is the relative mRNA level of IL-6, and J is the relative mRNA level of IL-12β.
[0023] Figure 6Figure 3 Effects of macrophage IL-27Rα knockdown on wound healing in diabetic mice; A is a flowchart of skin wound preparation and IL-27 intervention in genetic mice; B is photographing and observing wound healing in genetic mice; C is calculating the percentage of wound area at D8 / D0; D is H&E staining, Masson staining, and immunohistochemical staining of Arg-1 and CD31 in D8 wound tissue of genetic mice; E-G are relative quantifications of Arg-1, collagen, and CD31 expression in D8 wound tissue; H is a flowchart of skin wound preparation and single IL-27 intervention in genetic mice; I is H&E staining and immunohistochemical staining of F4 / 80, iNOS, and IL-1β in D2 wound tissue of genetic mice; J-L are relative quantifications of F4 / 80, iNOS, and IL-1β expression in D2 wound tissue; M is immunohistochemical staining to detect the expression of p-STAT3 in D2 wound tissue; and N is relative quantification of p-STAT3 expression in D2 wound tissue. DETAILED DESCRIPTION
[0024] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0025] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0026] Example 1 1. Experimental methods (1) Establishment of diabetic mice (DM): 8-week-old male C57 background mice were purchased from Guangdong Yaokang Biotechnology Co., Ltd. Five mice were housed in each cage under SPF conditions, with a 12-h light-dark cycle. All animal experiments were performed in accordance with the institutional guidelines and protocols approved by the Animal Care and Ethics Committee of Jinan University (approval number 20230724-17).
[0027] To induce diabetes, mice were injected with streptozotocin (STZ, Sangon Biotech, China). Model mice were intraperitoneally injected with STZ 100 mg / kg for 2 consecutive days, and non-diabetic mice were injected with vehicle (citrate buffer) only. After 9 days, tail vein blood glucose was measured by an automatic blood glucose meter to confirm the diabetic state. Mice with non-fasting blood glucose higher than 16.7 mmol / L were considered diabetic, and mice with less than 16.7 mmol / L were excluded from the study. The maintenance of the diabetic state of the mice was confirmed by weekly tail vein blood glucose measurements.
[0028] (2) Wound preparation plan: The backs of mice were shaved one day in advance. To prevent traumatic injuries to other mice, all mice were housed individually after shaving and surgery. On the day of surgery, the skin was scrubbed with 70% alcohol, and a full-thickness skin wound with a diameter of 6 mm was aseptically prepared. Skin specimens were collected on the 2nd and 8th days after trauma. Each specimen was fixed in paraformaldehyde for subsequent histopathological analysis. According to the experimental needs, as shown in the experimental flow chart, diabetic mice were intradermally injected with mrIL-27 at 200 ng / wound or 400 ng / wound using a 1 mL injection needle and injected for the corresponding number of days.
[0029] (3) Wound healing analysis: Digital photographs of the skin wound of each animal were taken at different time points, 0, 2, 4, 6, and 8 days after wounding. Wound closure was evaluated using Image J software. The percentage of unhealed wounds was calculated as: (area on day n) / (area on day 0) × 100.
[0030] (4) H&E staining: Fresh skin tissue was fixed in 4% paraformaldehyde for 24 hours and then dehydrated with graded alcohol. The tissue was embedded in a wax block for embedding. The embedded skin tissue was cut into 4-µm thick tissue sections. After the paraffin sections were dewaxed, hematoxylin was used to stain the nuclei and eosin was used to stain the cytoplasm. After staining, the sections were dehydrated, sealed, and dried to obtain image information. The sections were then scanned using a panoramic scanner (3D HISTECH, Hungary) to obtain high-definition images for observation and analysis.
[0031] (5) Immunohistochemical staining: Paraffin sections of skin tissue were first dewaxed and then antigen repaired. Endogenous peroxidase was blocked with 3% H2O2 at room temperature in the dark for 30 minutes. 10% serum corresponding to the source of the secondary antibody was added and incubated at 37°C for 30 minutes for blocking. Primary antibodies for IL-27 (R&D systems, USA), F4 / 80 (Proteintech, China), iNOS (Proteintech, China), IL-1β (Abcam, UK), Arg-1 (Proteintech, China), CD31 (Proteintech, China) and p-STAT3 (CST, USA) were purchased from the company and diluted separately for use. 200 μL of primary antibody working solution was added to each section and incubated overnight at 4°C. Secondary antibody working solution was added to each section and incubated at 37°C for 45 minutes. Freshly prepared DAB color development solution was added to each section, and the timer was used to time the color development. The color development was observed under a microscope and the color development reaction was terminated by washing with running water. The cell nuclei were stained with hematoxylin, and the sections were dried and sealed.
[0032] (6) Masson staining: Skin tissue sections are routinely dewaxed and rehydrated, and the dehydrated sections are immersed in Bouin solution overnight. Harris hematoxylin staining, hydrochloric acid-alcohol differentiation, and lithium carbonate is used to turn the color blue. Ponceau acid fuchsin staining, phosphomolybdic acid solution treatment for about 5 minutes, and aniline blue staining solution for 5 minutes. 1% glacial acetic acid treatment for 1 minute, 95% alcohol dehydration several times. The sections are dehydrated with anhydrous alcohol, transparentized with xylene, and sealed with neutral resin.
[0033] (7) IL-27 ELISA: Mouse peripheral blood was collected according to the manufacturer's instructions, allowed to stand at room temperature, and centrifuged to obtain the upper serum layer. A mouse IL-27 ELISA kit (Elabscience, China) was used to collect 100 μL of mouse serum. The absorbance was read at 450 nm using an ELISA reader, and the IL-27 concentration was calculated based on the standard curve.
[0034] (8) RNA extraction and quantitative real-time PCR (qPCR): Total RNA was isolated using Trizol (Takara, Japan) according to the manufacturer's protocol. The purity and concentration of RNA were determined by the Nano-Drop system (Thermo, USA). 1 μg of total RNA was reverse transcribed into cDNA using the HiScriptIII RT SuperMix for qPCR Kit (Vazyme, China). Real-time fluorescence quantitative PCR was performed using 2xRealStar Power SYBR qPCR Mix (Genstar, USA). The qPCR operation was as follows: incubation at 50°C for 2 min and at 95°C for 10 min. PCR was incubated at 95°C for 15 s and at 60°C for 1 min for a total of 40 cycles. At the melting curve stage, incubation was performed at 95°C for 15 s, 60°C for 1 min, and 95°C for 15 s. The gene expression in each sample was then analyzed using the QuantStudio™6 Pro Real-Time PCR System (Thermo Fisher Scientific, USA). β-actin mRNA was used as the internal reference. The relative expression of each gene was calculated using the 2-ΔΔCT formula. PCR primers are shown in Table 1: Table 1 PCR primers
[0035] (9) Western blotting: Samples were lysed in RIPA buffer. After centrifugation, the supernatant was collected and the protein concentration was determined using the Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, USA). Protein samples were separated on SDS-PAGE gels and transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked in 5% bovine serum albumin for 1 hour at room temperature and then washed three times with TBST. The membranes were trimmed and incubated with different primary antibodies overnight. After washing three times with TBST, the secondary antibodies were incubated for 1 hour at room temperature. After washing three times with TBST, they were exposed to Amersham ImageQuant 600 (GE Healthcare, USA). Western blotting was performed using primary antibodies against p-STAT3 (CST, USA), STAT3 (CST, USA), and β-Actin (Abclonal, China). Rabbit IgG (CST, USA) and mouse IgG (CST, USA) secondary antibodies were used.
[0036] (10) Statistical analysis: All data are expressed as mean ± SD. Graph Pad Prism 8.0 software (Graph Pad Prism software, La Jolla, CA, USA) was used to analyze the significant differences between two groups using unpaired t-test, and one-way analysis of variance was used to analyze the significant differences between multiple groups. P The difference was statistically significant when the value was <0.05.
[0037] 2. Result analysis: (1) The process of constructing a diabetic mouse model (DM) is as follows: Figure 1 A, The venous blood glucose levels in wild-type and diabetic mouse models (DM) are shown in 1B, indicating that diabetic mice were successfully modeled. The levels of IL-27, related mRNA and protein expressions in diabetic mice were measured, and the results showed that IL-27 expression was downregulated in the skin of diabetic mice ( Figure 1 C~H); Wounds were made in mice and treated with different concentrations of IL-27 from D1 to D7. The wound healing of mice was analyzed. The results showed that the addition of IL-27 promoted the wound healing of diabetic mice ( Figure 1 J~L).
[0038] (2) Wounds were prepared in diabetic mice and 400 ng / wound of IL-27 was injected at D1. Figure 2 A) and measured at D2, the results showed that the addition of IL-27 promoted the early M1 polarization of macrophages in the wound surface ( Figure 2B-E). Wounds were made in diabetic mice, and 400 ng / wound of IL-27 was injected on D1-D3 ( Figure 2 F), the wound healing status of mice was recorded every two days from the beginning of wound preparation and the percentage of wound area on D8 / D0 was calculated. The results showed that IL-27 promoted wound healing in diabetic mice ( Figure 2 G~H), the above results show that IL-27 accelerates the healing of diabetic wounds by promoting the polarization of early macrophages M1. Furthermore, diabetic mice were injected with 400ng / wound of IL-27 from D1 to D3 after wound preparation and measured on D8. The results showed that IL-27 intervention promoted the polarization of M2 macrophages in the wounds of diabetic mice ( Figure 3 B~D)、collagen deposition and angiogenesis( Figure 3 E~G). In summary, IL-27 can promote the early polarization of macrophages M1 in diabetic wounds, and then promote the polarization of macrophages M2 in wounds, ultimately accelerating the healing of diabetic wounds.
[0039] (3) The phosphorylation level of STAT3 in the skin tissue of WT and DM mice was detected. The results showed that the phosphorylation activation of STAT3 was inhibited in DM mice ( Figure 4 A, 4B), wounds were made in DM mice and IL-27 was injected at D1 ( Figure 4 C) The phosphorylation level of STAT3 in mouse skin tissue was detected at D2. The results showed that IL-27 promoted the phosphorylation and activation of STAT3 in macrophages ( Figure 4 D~E).
[0040] Example 2 The present invention found that IL-27 promoted the phosphorylation and activation of STAT3 in macrophages in DM mice, so the potential mechanism of IL-27 in promoting the healing of diabetic skin wounds was further explored. The specific method is as follows: The IL-27Rα knockdown mouse model was used for the experiment. IL-27ra flox / flox and Lyz-cre;IL-27raflox / flox mice were provided by Yin Zhinan from Jinan University. Five mice were housed in each cage under SPF conditions, with a 12-hour light-dark cycle. All animal experiments were performed in accordance with the institutional guidelines and protocols approved by the Animal Care and Ethics Committee of Jinan University (approval number 20231115-05).
[0041] Construction of IL-27Rα knockdown mouse model and mouse gene identification Figure 5 As shown in A and 5B, BMDM cells were obtained from the mouse model, separated and cultured, and stimulated with LPS, HG and IL-27 at the same time, as follows: (1) Culture of BMDM cells: Isolation and culture of BMDM cells: Bone marrow cells were washed from the tibia and femur of 8-week-old genetic mice using DMEM medium. The cells were then placed in DMEM medium containing 10% FBS and 10 ng / mL macrophage colony stimulating factor (MCSF, R&D systems, USA) and cultured at 37°C and 5% CO2 for 7 days.
[0042] (2) Glucose was dissolved in water to form a 2 M stock solution. LPS was purchased from R&D systems (USA) and diluted with water to a 5 mg / mL stock solution. Recombinant mouse IL-27 was purchased from Biolegend, USA. To investigate the mechanism of action of IL-27 on macrophages, we exposed BMDM cells to 1 μg / mL LPS, 50 mM HG, and 100 ng / mL IL-27 for 1 hour and 24 hours, respectively.
[0043] (3) Western blotting: BMDM cell samples were lysed in RIPA buffer. After centrifugation, the supernatant was collected and the protein concentration was determined using the Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, USA). Protein samples were separated on SDS-PAGE gels and transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked in 5% bovine serum albumin for 1 hour at room temperature and then washed three times with TBST. The membranes were trimmed and incubated with different primary antibodies overnight. After washing three times with TBST, the secondary antibodies were incubated for 1 hour at room temperature. After washing three times with TBST, they were exposed to Amersham ImageQuant 600 (GE Healthcare, USA). Western blotting was performed using primary antibodies against p-STAT3 (CST, USA), STAT3 (CST, USA), and β-Actin (Abclonal, China). Rabbit IgG (CST, USA) and mouse IgG (CST, USA) secondary antibodies were used.
[0044] (4) Statistical analysis: All data are expressed as mean ± SD. Graph Pad Prism 8.0 software (Graph Pad Prism software, La Jolla, CA, USA) was used to analyze the significant differences between two groups using unpaired t-test, and one-way analysis of variance was used to analyze the significant differences between multiple groups. P < 0.05 was considered statistically significant.
[0045] The results are as follows Figure 5As shown, the expression of IL-27Rα in BMDM cells extracted from IL-27Rα knockdown mouse model was detected and relative quantification was performed. After 1 hour of stimulation of BMDM cells with LPS, HG and IL-27, the phosphorylation activation of STAT3 was detected, and the relative protein level of p-STAT3 / β-actin was detected. After 24 hours of stimulation of BMDM cells with LPS, HG and IL-27, the relative mRNA levels of iNOS, IL-1β, IL-6 and IL-12β were detected. The results showed that IL-27Rα knockdown in macrophages ( Figure 5 C~D) inhibit STAT3 phosphorylation activation ( Figure 5 E~F) and macrophage M1 polarization ( Figure 5 G~J).
[0046] Skin wounds were created in genetic mice with macrophage IL-27Rα knockdown and IL-27 was used for intervention ( Figure 6 A), the results showed that knocking down macrophage IL-27Rα impaired skin wound healing in diabetic mice ( Figure 6 B~C). Knockdown of macrophage IL-27Rα inhibits macrophage M2 polarization, collagen deposition and angiogenesis in wound tissue of diabetic mice at D8 ( Figure 6 D~G). Knockdown of macrophage IL-27Rα inhibits macrophage infiltration and M1 polarization in D2 wound tissue of diabetic mice ( Figure 6 I~L). Mechanistically, knockdown of macrophage IL-27Rα inhibited the activation of p-STAT3 in the D2 wound tissue of diabetic mice ( Figure 6 M~N).
Claims
1. Use of IL-27 or an IL-27 expression promoter in the preparation of a drug for promoting diabetic wound healing.
2. The use according to claim 1, characterized in that: The diabetic wound surface is a diabetic ulcer.
3. The application according to claim 2, characterized in that: The diabetic ulcer is a diabetic foot ulcer.
4. The use according to claim 1, characterized in that: The drug promotes the healing of diabetic wounds by promoting the polarization of early macrophage M1 in the wound.
5. The use according to claim 1, characterized in that: The dosage of IL-27 in the drug is 7 to 15 ng / mm 2 .
6. The use according to claim 5, characterized in that: The dosage of IL-27 in the drug is 15 ng / mm 2 .
7. The use according to claim 1, characterized in that: The medicine also contains pharmaceutically acceptable excipients.
8. The use according to claim 7, characterized in that: The auxiliary material is at least one of a diluent, an excipient, a disintegrant, a filler, a binder, a lubricant, a surfactant, and a stabilizer.
9. The use according to claim 1, characterized in that: The dosage form of the drug is injection.
10. The use according to claim 9, characterized in that: The drug is administered by intradermal injection.
Citation Information
Patent Citations
Application of glehnia littoralis lactone in preparation of medicine for promoting healing of diabetic ulcer wound
CN113952333A
Novel IL27 receptor agonists and methods of use thereof
CN118451097A
